Brand and Other Names:Nuvigil
- Classes: Stimulants
Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule IV
Obstructive Sleep Apnea/Hypopnea Syndrome
150-250 mg PO qAM
150-250 mg PO qAM
Shift Work Sleep Disorder
150 mg PO qDay 1 hour prior to patient's work shift
Limitation of Use
In obstructive sleep apnea, indicated to treat excessive sleepiness and not as treatment for the underlying obstruction
Hepatic impairment: Reduce dose
Renal impairment: Safety and efficacy not established
Safety and efficacy not established
Consider lower initial dose
Serious - Use Alternative
Significant - Monitor Closely
Dry mouth (2-7%)
Attention disturbances (1%)
Contact dermatitis (1%)
Hypersensitivity to modafinil, armodafinil, or other ingredients
Not recommended in patients with angina, cardiac ischemia, recent history of myocardial infarction, left ventricular hypertrophy, or mitral valve prolapse
Use caution in patients with history of left ventricular hypertrophy/mitral valve prolapse who have had mitral valve prolapse syndrome when previously receiving CNS stimulants; consider increased monitoring
Use caution in severe hepatic impairment and the elderly
History of depression, psychosis, mania; consider discontinuing armodafinil if psychiatric symptoms develop
Consider dose adjustment of CYP3A4/5 substrate medications
May reduce effectiveness of steroidal contraceptives 1 month after discontinuation of drug therapy
If used adjunctively with continuous positive airway pressure (CPAP), periodic assessment of CPAP compliance is necessary
Toxic epidermal necrolysis, Stevens-Johonson syndrome, and life-threatening rashes reported; discontinue at first sign of serious rash
Discontinue therapy if symptoms suggest angioedema or anaphylaxis
Discontinue if multiorgan hypersensitivity is suspected
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown if excreted in milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Unknown; not sympathomimetic (R-enantiomer of modafinil); may increase dopamine levels in the brain by binding to the dopamine transporter and inhibiting dopamine reuptake
Peak plasma time: 2 hr
Protein bound: 60%
Vd: 42 L
Hepatic; primarily amide hydrolysis; also sulfone formation by CYP3A4/5
Enzymes induced: CYP1A2, possibly CYP3A4 in a concentration-related manner
Enzymes inhibited: CYP2C19
Half-life: 15 hr
Excretion: Urine (80%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs